Avidity Partners Management LP lessened its stake in Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) by 18.2% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 615,000 shares of the biotechnology company’s stock after selling 136,600 shares during the quarter. Blueprint Medicines accounts for approximately 2.1% of Avidity […]
Avidity Partners Management LP decreased its position in Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) by 18.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 615,000 shares of the biotechnology company’s stock after selling 136,600 shares during the quarter. Blueprint Medicines comprises […]
Eagle Asset Management Inc. raised its position in shares of Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) by 10.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 231,396 shares of the biotechnology company’s stock after acquiring an additional 22,279 […]
Shares of Blueprint Medicines Co. (NASDAQ:BPMC – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the seventeen research firms that are currently covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, five have assigned a hold recommendation, nine have given a buy recommendation and […]
Blueprint Medicines Co. (NASDAQ:BPMC – Get Free Report) has been assigned an average rating of “Moderate Buy” from the seventeen brokerages that are currently covering the stock, Marketbeat reports. Two research analysts have rated the stock with a sell recommendation, five have given a hold recommendation, nine have issued a buy recommendation and one has […]